Lonvoguran ziclumeran (lonvo-z)

Name: Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Current treatment options and standard of care
Published: 2026-09-14T15:39:06-04:00

Hereditary angioedema

Also known as NTLA-2002

Manufacturer: Intellia Therapeutics
Regulatory submission: Rolling BLA initiated April 2026 and accepted September 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

13 evidence topics · 10 sources

C1 esterase inhibitors1 evidence topic · 1 source
Plasma kallikrein inhibitors1 evidence topic · 1 source
Bradykinin b2 receptor antagonists1 evidence topic · 1 source
Factor XIIa inhibitors1 evidence topic · 1 source
Prekallikrein-directed antisense oligonucleotides1 evidence topic · 1 source
Attenuated androgens1 evidence topic · 1 source
Antifibrinolytics2 evidence topics · 1 source
Plasma replacement1 evidence topic · 1 source
Progestins1 evidence topic · 1 source
Supportive care and airway management1 evidence topic · 1 source
Limitations of current therapies2 evidence topics · 4 sources